失调
胰岛素抵抗
肠道菌群
微生物群
殖民抵抗
生物
粪便细菌疗法
疾病
代谢调节
脂质代谢
肠道微生物群
生物信息学
医学
不利影响
叙述性评论
代谢途径
代谢综合征
功能(生物学)
胰岛素
移植
免疫学
肥胖
新陈代谢
临床意义
炎症性肠病
免疫系统
炎症
碳水化合物代谢
人体研究
微生物代谢
β氧化
糖尿病
作者
Mohamad Al Qassab,Nadim Chaarani,Amira Hamou,Rasha Mustafa Harb,Ahmad Jradi,Mira Zeineddine,Hilda E. Ghadieh,Ziad Abi Khattar,Sami T. Azar,Amjad Kanaan,Frédéric Harb
标识
DOI:10.1096/fba.2025-00218
摘要
Emerging evidence highlights the pivotal role of the gut microbiota (GM) in regulating host metabolism and contributing to the development of insulin resistance (IR). Gut dysbiosis alters the production of critical metabolites, including short-chain fatty acids (SCFAs), bile acids, indole derivatives, and trimethylamine N-oxide (TMAO), which influence intestinal barrier integrity, inflammatory pathways, and glucose homeostasis. Recent clinical and translational studies indicate that SCFAs can improve fasting insulin and HOMA-IR, although the magnitude of benefit varies substantially across individuals, highlighting ongoing controversy surrounding their metabolic effects. Altered microbial regulation of bile-acid metabolism has also been implicated in impaired lipid and glucose signaling, reinforcing the relevance of FXR- and TGR5-mediated pathways in IR. Elevated TMAO levels have further been associated with adverse metabolic outcomes, though debate persists regarding its causal role versus its function as a diet-dependent biomarker. Microbiota-targeted strategies, including dietary fiber, probiotics, and fecal microbiota transplantation (FMT), show potential to modulate these metabolic pathways, yet clinical results remain inconsistent. This narrative review synthesizes recent mechanistic discoveries and clinical findings on microbiota-derived metabolites in IR, highlights key controversies, and outlines future priorities for translating microbiome science into effective and personalized interventions for metabolic disease prevention and management.
科研通智能强力驱动
Strongly Powered by AbleSci AI